A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Sponsor: Merck Sharp & Dohme LLC
ClinicalTrials ID:NCT06952504
This study evaluates the efficacy of sacituzumab tirumotecan with pembrolizumab versus pembrolizumab alone in pMMR endometrial cancer. Participants undergo an Induction Phase with pembrolizumab, carboplatin, and paclitaxel or docetaxel. Those with non-progressive cancer enter a Maintenance Phase, receiving either pembrolizumab with sac-TMT or pembrolizumab alone.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.
- EC is a type of cancer that starts in the tissues inside the uterus (womb)
- pMMR indicates that certain normal proteins are present in the cancer cells
- Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery
- Recurrent means the cancer came back after surgery
Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.
The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Description
All participants undergo an initial Induction Phase of six cycles, each cycle consisting of pembrolizumab + carboplatin + paclitaxel or docetaxel. Each cycle is three weeks. Participants whose cancer does not progress enter the Maintenance Treatment Phase and are then randomly assigned to pembrolizumab + sac-TMT or pembrolizumab monotherapy. Participants whose cancer does progress will have the possibility to enter the Subsequent Treatment Phase and are then randomly assigned to pembrolizumab + sac-TMT or sac-TMT monotherapy.
Eligibility Criteria
Key inclusion criteria include but are not limited to:
- Has a histologically confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that has been confirmed as proficient mismatch repair (pMMR)
- Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator.
- Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment
Key exclusion criteria include but are not limited to:
- Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of sarcomas
- Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR)
- Is a candidate for curative-intent surgery or curative-intent radiotherapy at the time of enrollment
- Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Received prior therapy in any setting with any of the following: anti-programmed cell death 1 protein, anti-programmed cell death ligand 1, anti-programmed cell death ligand 2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor; trophoblast cell surface antigen 2-targeted antibody drug conjugate; or topoisomerase I inhibitor-containing antibody drug conjugate
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of South Alabama, Mitchell Cancer Institute ( Site 6033) | 36604 | Mobile | Alabama |
| Alaska Women's Cancer Care ( Site 6036) | 99508 | Anchorage | Alaska |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) | 92868 | Orange | California |
| MedStar Washington Hospital Center ( Site 5005) | 20010 | Washington D.C. | District of Columbia |
| Florida Cancer Specialists - South ( Site 7003) | 33901 | Fort Myers | Florida |
| UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026) | 32608 | Gainesville | Florida |
| Mount Sinai Cancer Center ( Site 6031) | 33140 | Miami Beach | Florida |
| Florida Cancer Specialists - North ( Site 7002) | 33705 | St. Petersburg | Florida |
| Florida Cancer Specialists East ( Site 7001) | 33401 | West Palm Beach | Florida |
| St. Joseph's/Candler Health System ( Site 6021) | 31405 | Savannah | Georgia |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.